相似文献
1
Hormonal therapies: ADT for prostate cancer: true love or heartbreak?
Nat Rev Clin Oncol. 2010 Mar;7(3):130-2. doi: 10.1038/nrclinonc.2010.12.
2
Prostate cancer: Say no to ADT for localized disease.
Nat Rev Urol. 2014 Sep;11(9):487. doi: 10.1038/nrurol.2014.187. Epub 2014 Jul 29.
3
Treating asymptomatic patients with hormone-refractory prostate cancer: hormonal manipulations for the urologist.
BJU Int. 2008 Mar;101(6):671-4. doi: 10.1111/j.1464-410X.2007.07336.x. Epub 2007 Dec 7.
4
Primary androgen deprivation therapy in men with prostate cancer.
JAMA. 2009 Jan 7;301(1):35; author reply 35. doi: 10.1001/jama.2008.903.
5
Prostate cancer: is androgen-deprivation therapy chosen wisely?
Nat Rev Clin Oncol. 2014 Sep;11(9):501. doi: 10.1038/nrclinonc.2014.130. Epub 2014 Jul 29.
6
Prostate cancer: Why statins are beneficial.
Nat Rev Urol. 2015 Jul;12(7):360. doi: 10.1038/nrurol.2015.125. Epub 2015 May 26.
7
Hormone-refractory prostate cancer: what have we learned?
BJU Int. 2007 Jul;100 Suppl 2:56-9. doi: 10.1111/j.1464-410X.2007.06957.x.
8
Progress in Understanding What Is Being Statin(ed) in Prostate Cancer.
JAMA Oncol. 2015 Jul;1(4):428-30. doi: 10.1001/jamaoncol.2015.0833.
9
Measuring the effectiveness of androgen-deprivation therapy for prostate cancer in the medicare population: adequate data are neither the same as nor the enemy of perfect data.
JAMA Intern Med. 2014 Sep;174(9):1468-9. doi: 10.1001/jamainternmed.2014.1107.
10
Intermittent androgen suppression. Too good to be true?
Scand J Urol Nephrol Suppl. 1999;203:45-9. doi: 10.1080/003655999750169376.
引用本文的文献
1
Cardiovascular Mortality Following Short-term Androgen Deprivation in Clinically Localized Prostate Cancer: An Analysis of RTOG 94-08.
Eur Urol. 2016 Feb;69(2):204-10. doi: 10.1016/j.eururo.2015.08.027. Epub 2015 Sep 9.
本文引用的文献
1
Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction.
JAMA. 2009 Aug 26;302(8):866-73. doi: 10.1001/jama.2009.1137.
2
Impact of androgen deprivation therapy on cardiovascular disease and diabetes.
J Clin Oncol. 2009 Jul 20;27(21):3452-8. doi: 10.1200/JCO.2008.20.0923. Epub 2009 Jun 8.
3
Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.
J Clin Oncol. 2009 Jan 1;27(1):92-9. doi: 10.1200/JCO.2007.12.3752. Epub 2008 Dec 1.
4
Cardiovascular mortality and duration of androgen deprivation for locally advanced prostate cancer: analysis of RTOG 92-02.
Eur Urol. 2008 Oct;54(4):816-23. doi: 10.1016/j.eururo.2008.01.021. Epub 2008 Jan 15.
5
Short-term neoadjuvant androgen deprivation therapy and external-beam radiotherapy for locally advanced prostate cancer: long-term results of RTOG 8610.
J Clin Oncol. 2008 Feb 1;26(4):585-91. doi: 10.1200/JCO.2007.13.9881. Epub 2008 Jan 2.
6
Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions.
J Clin Oncol. 2007 Jun 10;25(17):2420-5. doi: 10.1200/JCO.2006.09.3369.
7
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.
J Clin Oncol. 2006 Sep 20;24(27):4448-56. doi: 10.1200/JCO.2006.06.2497.
8
The rising prevalence of androgen deprivation among older American men since the advent of prostate-specific antigen testing: a population-based cohort study.
BJU Int. 2006 Nov;98(5):973-8. doi: 10.1111/j.1464-410X.2006.06416.x. Epub 2006 Jul 28.
9
Caveat medicus: consequences of federal investigations of marketing activities of pharmaceutical suppliers of prostate cancer drugs.
J Clin Oncol. 2005 Dec 1;23(34):8894-905. doi: 10.1200/JCO.2005.01.4605.
10
Impact of short course hormonal therapy on overall and cancer specific survival after permanent prostate brachytherapy.
Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1299-305. doi: 10.1016/j.ijrobp.2004.08.024.
Zotero 插件